Bin Wu

Founder & Chief Executive Officer Cytodigm

Seminars

Wednesday 30th September 2026
Workshop B: Advancing Extrahepatic Delivery to Improve Safety & Targeting for Genome Editing Therapeutics
1:45 pm

Redirecting gene editing vectors away from the liver whilst maintaining effective dosing remains one of the field’s most pressing delivery challenges. Join this workshop to explore real-world applications of reducing LNP and AAV liver tropism, enhancing tissue-specific targeting and investigating exosomal delivery approaches, giving you practical strategies to improve both safety and therapeutic efficacy.

Workshop highlights:

  • Exploring real-world approaches to reducing LNP and AAV liver tropism, equipping you with strategies to improve the safety profile of your therapeutics
  • Examining methods for enhancing tissue-specific targeting of delivery vectors, enabling you to direct therapies more precisely to the right disease area
  • Investigating exosomal delivery as an emerging alternative to viral and lipid vectors, giving you a broader toolkit for extrahepatic genome editing applications
  • Balancing safety and effective dosing in extrahepatic delivery design, helping you develop therapeutics that meet regulatory expectations without compromising efficacy
Bin Wu, Founder and CEO of Cytodigm, presenting innovative delivery technologies to expand genome editing applications beyond traditional targets at the 7th Genome Editing Therapeutics Summit 2026